Detailed Information

A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)

Cited 0 time in Web of Science Cited 0 time in Scopus

Baek, Sun Kyung; Jeong, Jae-ho; Jung, Kyunghae; Ahn, Hee Kyung; Kim, Min Hwan; Sohn, Joohyuk; Park, In Hae; Ahn, Jin Seok; Lee, Dae-Won; Im, Seock-Ah; Sim, Sung Hoon; Lee, Keun Seok; Hyun Kim, Jee; Shim, Hyun-Jeong; Chae, Yeesoo; Koh, Su-Jin; Lee, Hyorak; Lee, Jieun; Byun, Jae-Ho; Seol, Youngmi; Lee, Eun Mi; Jee, Hee-Jung; An, Hyonggin; Park, Eun Byeol; Suh, Young Ju; Lee, Kyoung Eun; Park, Yeon Hee

Issue Date
SAGE Publications
Therapeutic Advances in Medical Oncology, Vol.16, pp.1-15
Purpose: This study aimed to investigate clinical practices and factors related to the outcomes of T-DM1 use in patients with HER2-positive metastatic breast cancer (mBC). Methods: We included patients with HER2-positive mBC who received T-DM1 as a palliative therapy between August 2017 and December 2018. The safety and outcomes of T-DM1, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), were evaluated. A Cox proportional hazards model was used to estimate the hazard ratio and 95% confidence interval (CI) for mortality or progression to HER2-positive mBC. Results: In total, 824 patients were enrolled during the study period. The mean age of patients was 58 years, and 516 (62.6%) patients relapsed after curative treatment. Excluding a history of endocrine therapy, 341 (41.4%) patients previously received none or first-line chemotherapy, 179 (21.7%) received second-line therapy, and 303 (36.9%) received third-or later-line chemotherapy before T-DM1 therapy. During a median follow-up of 16.8 months, the ORR was 35%, the median PFS was 6.6 months, and the median OS was not reached. The clinical factors associated with the hazard of progression were age (<65 years), poor performance status (>2), advanced line of palliative chemotherapy (>2), prior pertuzumab use, and treatment duration of palliative trastuzumab (<10 months). Common grade 3-4 adverse events were thrombocytopenia (n = 107, 13.2%), neutropenia (n = 23, 2.8%), anemia (n = 21, 2.6%), and elevated liver enzyme (n = 20, 2.5%). Hypokalemia (<= 3.0 mmol/L) and any-grade bleeding events occurred in 25 (3.1%) and 94 (22.6%) patients, respectively. Conclusion: This is the first nationwide real-world study of T-DM1 use in patients with HER2-positive mBC in Korea. The effectiveness and toxicity profiles of T-DM1 in real-world practice were comparable to those in randomized trials. Moreover, patient factors and previous anti-HER2 therapy could predict the outcomes of T-DM1 therapy.
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Clinical Medicine


Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.